Table 2.
Univariate analysis | |||||
---|---|---|---|---|---|
n | Median (days) | P-value | HR | 95% CI | |
Cohort | |||||
Allo | 35 | 23 | Ref | ||
Auto | 94 | 11 | 0.005 | 1.75 | 1.18–2.60 |
CD34+ | |||||
Min–Q3 | 74 | 16.5 | Ref | ||
Q3–Max | 25 | 9 | <0.001 | 2.65 | 1.65–4.25 |
CD34+MA6+ | |||||
Min–Q1 | 32 | 24 | Ref | ||
Q1–Q3 | 64 | 12.5 | 0.005 | 1.88 | 1.21–2.92 |
Q3–Max | 33 | 9 | <0.001 | 6.03 | 3.48–10.46 |
HR, hazards ratio.